经宫颈注射18F-FDG正电子淋巴管显像用于宫颈及子宫内膜恶性肿瘤术前淋巴绘图
本研究为首次人体试点临床试验(NCT02285192),纳入23例子宫或宫颈癌患者,于手术当日经宫颈注射18F-FDG后行盆腔动态PET/CT及1小时延迟全身扫描,以评估正电子淋巴管显像(PLG)识别肿瘤阳性淋巴结的能力。最终病理证实3例(15%)淋巴结阳性,PLG全部识别(包括1个仅含80个肿瘤细胞的病灶),另有2例(10%)PLG假阳性。作者认为PLG在此人群中可行且能识别淋巴结转移患者,需进一步研究评估。
要点
- 23例子宫或宫颈癌患者中,最终病理证实3例(15%)淋巴结阳性,PLG全部识别。
- PLG识别出全部阳性淋巴结,包括1个仅含80个肿瘤细胞的病灶。
- PLG出现2例(10%)假阳性,对应前哨淋巴结最终病理为阴性。
核心结论
- 这项首次人体研究显示,在子宫及宫颈癌女性中PLG可行,并能识别淋巴结转移患者,需在更多研究中进一步评估。
研究设计与样本
- 首次人体试点临床试验(临床试验标识NCT02285192),纳入23例子宫或宫颈癌患者。
- 手术当日早晨经宫颈注射18F-FDG,随即行盆腔动态PET/CT,并加做1小时延迟全身扫描。
- 此前已在动物模型中显示PLG能识别转移淋巴结。
主要发现
- 最终病理分析有3例(15%)淋巴结阳性,PLG识别出全部这些淋巴结,包括1个仅含80个肿瘤细胞的病灶。
- PLG有2例(10%)假阳性,对应前哨淋巴结最终病理为肿瘤阴性。
- 目前前哨淋巴结绘图需淋巴结活检做病理评估,因为尚无临床影像方法能在早期识别肿瘤阳性淋巴结。
- 在80%-90%的患者中,探查的淋巴结最终无肿瘤,意味着多数患者不必要地接受了淋巴结清扫术。
临床怎么用
- 作者认为PLG在此人群中可行且能识别淋巴结转移患者,并指出需在更多研究中进一步评估。
局限性
- 原文结论指出需在更多研究中进一步评估(warrants further evaluation in additional studies)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The presence of metastasis in local lymph nodes (LNs) is a key factor influencing choice of therapy and prognosis in cervical and endometrial cancers; therefore, the exploration of sentinel LNs (SLNs) is highly important. Currently, however, SLN mapping requires LN biopsy for pathologic evaluation, since there are no clinical imaging approaches that can identify tumor-positive LNs in early stages. Staging lymphadenectomy poses risks, such as leg lymphedema or lymphocyst formation. Furthermore, in 80%-90% of patients, the explored LNs are ultimately tumor-free, meaning most patients are unnecessarily subjected to lymphadenectomy. Methods: Current lymphoscintigraphy methods identify only the anatomic location of the SLNs and do not provide information on their tumor status. There are no noninvasive methods to reliably identify metastases in LNs before surgery. We have developed positron lymphography (PLG), a method to detect tumor-positive LNs, in which 18F-FDG is injected interstitially into the uterine cervix on the day of surgery, and its rapid transport through the lymphatic vessels to the SLN is then visualized with dynamic PET/CT. We previously showed that PLG was able to identify metastatic LNs in animal models. Here, we present the first results from our pilot clinical trial (clinical trials identifier NCT02285192) in 23 patients with uterine or cervical cancer. On the morning of surgery, 18F-FDG was injected into the cervix, followed by an immediate dynamic PET/CT scan of the pelvis and a delayed 1-h whole-body scan. Results: There were 3 (15%) node-positive cases on final pathologic analysis, and all of these LNs (including 1 with a focus of only 80 tumor cells) were identified by PLG. There were 2 (10%) false-positive cases with PLG, in which the final pathology of the corresponding SLNs was negative for tumor. Conclusion: This first-in-humans study of PLG in women with uterine and cervical cancer demonstrates its feasibility and its ability to identify patients with nodal metastases and warrants further evaluation in additional studies.
引用
- Mueller JJ, Dauer LT, Murali R, et al. Positron Lymphography via Intracervical 18F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies. J Nucl Med. 2020. PMID: 31924717. doi:10.2967/jnumed.119.230714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。